Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers.

Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers.

Geldenhuys Werner; Mbimba Thomas; Bui Thong; Harrison Kimberly; Sutariya Vijaykumar

Journal of drug targeting

2011

2011-11

Paclitaxel is not effective for treatment of brain cancers because it cannot cross the blood-brain barrier (BBB) due to efflux by P-glycoprotein (P-gp). In this work, glutathione-coated poly-(lactide-co-glycolide) (PLGA) nanoparticles (NPs) of paclitaxel were developed for brain targeting for treatment of brain cancers. P-gp ATPase assay was used to evaluate the NP as potential substrates. The NP showed a particle size suitable for BBB permeation (particle size around 200 nm) and higher cellular uptake of the NP was demonstrated in RG2 cells. The

Humans; Male; Animals; Mice; *Drug Delivery Systems; Rats; Cell Line; Nanoparticles; Permeability; Particle Size; Delayed-Action Preparations; Blood-Brain Barrier/metabolism; Adenosine Triphosphatases/metabolism; Brain Neoplasms/drug therapy; Cell Death/drug effects; Coumarins/administration & dosage/pharmacokinetics; Glioma/drug therapy/pathology; Glutathione/*chemistry; Microtubules/metabolism; Paclitaxel/administration & dosage/*pharmacokinetics/pharmacology; Thiazoles/administration & dosage/pharmacokinetics; Tubulin/metabolism; Inbred C57BL; Tumor; ATP Binding Cassette Transporter; Antineoplastic Agents; Member 1/metabolism; Subfamily B; Phytogenic/administration & dosage/*pharmacokinetics/pharmacology

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

837–845

9

19